Ruti Aga: Six Years Suspended, and Four of Them Written by a Fake Prescription

Ruti Aga: Six Years Suspended, and Four of Them Written by a Fake Prescription

The sanction runs from 10 September. Ruti Aga is 32. Six years.

The conventional reading stops at the word doping. Mine stops at the arithmetic: 2 + 4. Two years for the presence of methylprednisolone in a sample. Four years for a prescription. The larger part of the sentence does not sit in a test tube. It sits in a clinic that does not exist, signed by a relative with no medical registration number, written on an old prescription pad from a facility that has confirmed the person never worked there.

Four years for a piece of paper.

If anyone wants to understand why the anti-doping system grows more expensive year on year, this is where to look. Cost is not rising at sample collection. Cost is rising at document verification — calling the clinic, checking the registration number, cross-referencing employment records. Things almost nobody did a decade ago, because forged paperwork of that era was still good enough to pass.

I have watched road running long enough to know one thing: a results board and an administrative file are two different layers of data. The first is published and legible to anyone. The second only surfaces when somebody knocks on a door.

Credentials: the sanctioned athlete is not a nobody

Ruti Aga won the 2026 Tokyo Marathon. She has three runner-up finishes at World Marathon Majors — the six most prestigious road races on the planet: Tokyo, Boston, London, Berlin, Chicago and New York. The published material does not specify which three races those podium finishes came at; I flag this as data pending verification, though the count alone establishes the tier.

Across the 2026–2026 window, that is the record of a genuine elite of women's marathon running, not a name inserted to fill an invitation quota. She was 32 when the ban took effect. For female marathoners, the peak window commonly extends to 35 and beyond. The sanction therefore lands precisely when an athlete generates her highest competitive and commercial value — not during decline.

Six years from 10 September returns her at roughly 38. Biologically, a female marathoner can still race at elite level at 38. Structurally, someone who has spent six consecutive years suspended, with no official results, no invitations, no ranking, is very unlikely to return to World Marathon Majors podium level. This is a career-ending sanction, not a career interruption.

I note the point because it changes how the whole case reads. A 23-year-old given six years still has a decade ahead. A 32-year-old given six years is having the remainder taken away.

Re-reading the label: methylprednisolone is not an anabolic steroid

Most reporting calls methylprednisolone a steroid. I need to correct that, because it bears directly on how the sanction is understood.

Methylprednisolone is a synthetic glucocorticoid — a corticosteroid, not an anabolic-androgenic steroid. In the World Anti-Doping Agency (WADA) list it sits in class S9, prohibited in-competition but permitted out-of-competition. More importantly, it is a Specified Substance — a category recognised as more plausibly linked to inadvertent or therapeutic use.

Those three features reshape the entire sanction framework. The baseline for a Specified Substance without evidence of intent is two years, and in many cases it can drop lower where the athlete establishes source and no significant fault.

In other words, the substance half of this case was the soft half. It is the most defensible territory in the whole WADA system. An athlete who tests positive for a corticosteroid in competition, with a documented history of knee injury and a legitimate treatment record, has a real exit — through a valid TUE (Therapeutic Use Exemption), or through an honest disclosure of a therapeutic error.

Aga did not walk through that door. She built a different one.

This is why I always read the substance description before the sanction description. If the substance is an anabolic steroid, two years is a reasonable floor and six years is the product of an aggravating circumstance. If the substance is a Specified glucocorticoid, two years is already the default ceiling, and the remaining four must come from somewhere else. It came from the paper.

The evidence chain: four years of a document

The Athletics Integrity Unit (AIU) — World Athletics' independent body handling testing, results management and prosecution — reconstructed the sequence tightly.

A prescription was produced to explain the adverse finding. It named a clinic. That clinic does not exist. The signatory was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace. The facility named confirmed the person had never been on staff. And a second facility, alleged to have issued the document, denied it was theirs.

Five links. Each independent of the other four. Nowhere for it to give.

I have sat in meetings where people argued for hours over a PPDA figure differing by 0.3 units. That experience taught me to separate two kinds of file: one supported by a single pillar, and one supported by several independent pillars. The first collapses when its pillar is kicked away. The second does not, because kicking one leaves four standing.

The AIU file is the second kind. This is why I rate the chances of a successful appeal on the tampering finding as very low, however strong Aga's counsel may be.

The stacking mechanism also needs stating, because it is widely misread. The WADA Code provides that where an athlete commits multiple anti-doping rule violations, the periods are served consecutively, not concurrently. Two years for presence. Four years for tampering during results management. Six years total — not four, not two plus a remainder.

And here is the core point: the cover-up was punished at twice the rate of the doping itself. The penalty for concealment exceeded the penalty for the underlying offence.

I tested the reverse hypothesis before settling on that. The counter-argument runs like this: perhaps the AIU stacked two charges for public effect, and four years is a discretionary maximum. I reject it on the structure of the evidence. Four years is the baseline for tampering under the WADA Code, not an inflated figure. The AIU did not need to exaggerate — it needed only to list five links and let the arithmetic run.

The second notable element sits on the investigating side. The AIU calling a clinic directly, checking a registration number, verifying employment history at a medical facility — that is standard procedure, not a special investigation. The technological barrier has fallen to the point where a family-built forgery is near-certain to be detected within weeks.

The anti-doping fight has shifted. A decade ago the question was how to detect a substance in a sample. Now the question is how to verify a document. And documents are far easier to check than blood.

The road-racing economy: the unpublished layer

The triggering result was a half marathon win in China in March. The published material does not disclose the time.

That is a significant data gap, and I would rather name it than paper over it with inference. Without a mark, I cannot position that performance against the course record, against Aga's personal best, or against the general standard of elite women's road running. Any claim about the sporting significance of that win is speculation.

But there is another layer that reads fine without a mark: the economic structure of Chinese road races.

That market runs on appearance fees. Organisers pay to bring East African athletes in, because an Ethiopian or Kenyan name on the start list raises the race's prestige and its broadcast value. Athletes receive cash, often tied to finishing position. It is an income stream parallel to official prize money, and for most road racers it is larger.

Haiphong taught me that a star is not on the shirt, it is in the index. I extend that to road running: a star is not on the results board, it is in the appearance contract. A runner-up at a small race can earn more than a winner at a large one, depending on how the deal is built.

The consequences of this ban at that layer are concrete. The Chinese result is almost certainly annulled. Prize money is forfeited. Appearance fees already paid may be clawed back under contract terms. And above all: six years without appearance-fee income, without World Marathon Majors invitations, without sponsorship deals.

For an elite marathoner, those three streams — appearance fees, major prize money, sponsorship — account for essentially all income. All three close at once.

Counter-argument: correlation is not causation

Here I have to break my own easiest reading.

The easy reading is: a six-year ban proves this case is three times as serious as an ordinary doping case. That is not logically sound. The length of the sanction here measures the quality of the paperwork, not the quantity of substance or its effect on performance.

An athlete who uses erythropoietin for months, systematically, with a doctor's support, may receive four years. An athlete who uses a corticosteroid for a knee and then fabricates a prescription may receive six. The second number is larger, but it does not say the second act is more dangerous to the sport. It says the second act attacks the verification system, and the verification system is what a regulator cannot allow to be attacked.

Misreading this produces a media consequence: the public will picture a large-scale doping ring, when what is actually described is an amateur, clumsy cover-up lacking both medical and legal literacy. A clinic that does not exist. An old pad. A relative signing. Those three details are not the signature of a sophisticated operation. They are the signature of a medical and legal support structure so thin as to be pitiful around a world-class athlete.

People call me a data monk. A monk does not need a cathedral, only the truth. And the truth here is: this case proves nothing about the Ethiopian road-running system. It proves one thing about the compliance support infrastructure around East African athletes.

I also have to correct a mistake of my own. On first pass I read the word steroid and assumed an anabolic, class S1 or A3 in the WADA list. That assumption was wrong. On checking, methylprednisolone is an S9 glucocorticoid, in-competition only, and Specified. Had I kept the wrong assumption, the entire sanction analysis above would have been skewed — I would have explained six years as a reasonable penalty for a dangerous substance, rather than as a penalty for a document.

This is why I always re-check the substance label before re-checking the sanction. The label sets the frame. The frame sets the conclusion.

A second counter-argument deserves airing: does this ban change the competitive balance of women's marathon running? On the evidence of Ethiopian and Kenyan depth, essentially not. Both nations run a development pipeline so deep that a lost slot is refilled within a season, usually by someone younger, cheaper, and without a file to scrutinise.

An athlete removed from that system is a replaceable node. What is damaged is not the competitive balance but the reputational premium of the Ethiopian road-running brand — commercially valuable to agents, organisers and sponsors.

Missing data: what I cannot conclude

I do not want to close the analysis in a tone of absolute certainty, because the published record does not permit it.

First, the route of administration is not stated. An intra-articular injection close to competition would plainly trigger the in-competition prohibition and make the knee-injury account far more plausible. An oral route paints a different picture. Without this, I cannot assess the credibility of the medical explanation.

Second, there is no information on whether Aga ever sought a TUE. That is the decisive question. If she never applied, the root error was administrative, and administrative errors can be fixed by honest disclosure. If she applied and was refused, constructing a fake prescription is a far more deliberate act.

Third, the specific years of the March adverse finding and of the 10 September provisional suspension are not stated in the published material. I flag this as data pending verification. A complete timeline would show the gap between test and sanction — and that gap measures the system's processing speed.

Fourth, there is no indication whether Aga will appeal to the Court of Arbitration for Sport. That is the only procedural lever left. Against a file of five independent links, the expectation of success on the tampering finding is low.

Fifth, and this is what I am watching most closely: the possibility of retrospective review of stored samples. When a case concludes with a tampering finding, reopening the long-term sample store and the athlete's biological passport is a procedurally logical step. If it happens, older results — including the ones that built her standing — could return to the table.

I list these five gaps not to dodge a conclusion. I list them because a conclusion that does not state its own limits is an unfinished conclusion.

Signals for the next cycle

The road runs one way. Data sees every direction.

The first direction to watch is the entourage layer. Tampering cases are rarely built by one person alone. Someone helped draft the document, someone advised on the defence strategy, someone decided that a clinic which does not exist was a good enough idea. If the AIU widens its investigation to that layer, it will be a far stronger signal than the six-year figure itself.

The second is the Chinese race-organiser side. That market runs on appearance fees and on the credibility of its start lists. After a case tied to a half marathon there, tightening medical and treatment-document vetting for invited athletes is the logical move to protect reputation.

The third, and structurally the most interesting to me: compliance support infrastructure for East African road runners. An athlete who won the Tokyo Marathon and finished runner-up at three World Marathon Majors had nobody beside her who understood that a legitimate prescription plus an honest declaration costs far less than an old prescription pad.

The distance between those two options is not a moral distance. It is an information distance. And information distances can be measured, standardised and closed — if somebody is willing to pay for it.

Six years from now, when Aga is 38, someone will ask why a woman who ran 42.195 kilometres at world level ended her career with a piece of paper. I will answer with another question: over those six years, how many young Ethiopian athletes were taught how to apply for a TUE before they were taught how to run faster?

If the answer is still no, then the six-year ban is only a full stop in a sentence that has not yet ended.